Audentes Therapeutics Inc. (BOLD)

33.9 +0.69 (+2.078%)

IEX Real-Time Price

February 23, 2018 EST.

NASDAQ Global Market : Healthcare

Prev Close 33.21

Price Open 34.28

Volume: 164,563

Avg Volume: 432,314

Market Cap: 1.01B

P/E Ratio -9.71

52 Wk Range 13.8979-41.8



BOLD Short Interest Statistics


Report Date
Float Share
Short Interest
Short Ratio
Short % to Float

2018-01-31
29.31M
1.66M
2.55
5.65%

2018-01-12
29.31M
964,664
2.25
3.29%

2017-12-29
29.3M
896,597
4.09
3.06%

2017-12-15
29.3M
834,189
3.27
2.85%




BOLD Earning Report


Report Date
Fiscal Period
Announce Time
Estimated EPS(#)
Actual EPS
Surprise Dollar

2018-03-08
Q4 2017
N/A
-0.92 (7)
0.00
0.00

2017-11-14
Q3 2017
AMC
-0.86 (5)
-0.88
-0.02

2017-08-10
Q2 2017
N/A
-0.79 (4)
-0.87
-0.08

2017-05-11
Q1 2017
N/A
-0.92 (5)
-0.83
0.09

News

3 Things In Biotech You Should Learn Today: February 14, 2018 (2018-02-15 08:00 SeekingAlpha)

Note: Subscribers to Avisol Capital Partners Total Pharma Tracker got an early look at this publication. Welcome to another edition of "3 Things In Biotech You Should Learn Today," a daily digest dedicated to helping you keep pace with the fast-moving world of pharmaceutical and biotechn…

 

Audentes Therapeutics Announces Dosing of First Patient in VALENS, a Phase 1/2 Clinical Trial of AT342 for the treatment of Crigler-Najjar Syndrome (2018-02-12 08:00 PR Newswire)

SAN FRANCISCO , Feb. 12, 2018 /PRNewswire/ --Audentes Therapeutics, Inc.(Nasdaq: BOLD), a biotechnology company focused on developing and commercializing gene therapy products for patients living with serious, life-threatening rare diseases, today announced it has commenced do…

 

Audentes Therapeutics to Present at the LEERINK Partners 7th Annual Global Healthcare Conference (2018-02-08 08:00 PR Newswire)

SAN FRANCISCO , Feb. 8, 2018 /PRNewswire/ --Audentes Therapeutics, Inc.(Nasdaq: BOLD), a biotechnology company focused on developing and commercializing gene therapy products for patients living with serious, life-threatening rare diseases, today announced that Matthew R. Pat…

 

Audentes Therapeutics Announces Selection of Optimized Clinical Development Candidate for Pompe Disease Program (2018-02-06 19:30 PR Newswire)

SAN FRANCISCO , Feb. 6, 2018 /PRNewswire/ --Audentes Therapeutics, Inc.(Nasdaq: BOLD), a biotechnology company focused on developing and commercializing gene therapy products for patients living with serious, life-threatening rare diseases, today announced it has selected an o…

 

Audentes Therapeutics Announces the Closing of its Public Offering and Full Exercise of the Underwriters' Option to Purchase Additional Shares (2018-01-29 16:01 PR Newswire)

SAN FRANCISCO , Jan. 29, 2018 /PRNewswire/ --Audentes Therapeutics, Inc. (Nasdaq: BOLD), a clinical stage biotechnology company focused on developing and commercializing gene therapy products for patients living with serious, life-threatening rare diseases, today announced the closi…

 

Audentes prices 5.75M-share offering at $35 (2018-01-24 19:52 SeekingAlpha)

Audentes Therapeutics (NASDAQ: BOLD ) has priced the public offering it announced yesterday. More news on: Audentes Therapeutics, Healthcare stocks news, Stocks on the move, Read more …

 


Statistics

Shares Outstanding: 29.86M

Top 15 Institution Percent: 89.40

Price To Sales: N/A

Price To Book: 5.66

Revenue: N/A

Gross Profit: N/A

Cash: 487.66M

Debt: N/A

Return On Assets: -46.74

Return On Equity: -53.49

Profit Margin: N/A

Price History

Beta: 0.87

50-day Moving Avg: 33.77

200-day Moving Avg: 24.83

YTD Change: -294.90

5-day Change: -1.14

1-month Change: -9.14

3-month Change: 20.51

6-month Change: 81.38

1-year Change: 120.13

Revenue Per Share: 0.00

Revenue Per Employee: 0.00



Dividend

Dividend Yield: -

EX-Dividend Date: -

Dividend Rate: -


Company Profile

Name: Audentes Therapeutics Inc.

Exchange: NASDAQ Global Market

Industry: Biotechnology

Sector: Healthcare

Website: http://www.audentestx.com

Audentes Therapeutics Inc is a biotechnology company. It is engaged in developing and commercializing gene therapy products for patients suffering from serious, life-threatening rare diseases caused by single gene defects.